Categories AlphaGraphs, Earnings, Health Care
VRTX Earnings: A snapshot of Vertex Pharmaceuticals’ Q1 2023 results
Healthcare firm Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) on Monday reported a decline in adjusted earnings for the first quarter, despite an increase in revenues.
Total revenues increased to $2.37 billion in the first quarter from $2.10 billion in the corresponding period of 2022. For the full fiscal year, the management expects product revenues to be between $9.55 billion and $9.70 billion.
Meanwhile, adjusted earnings dropped to $3.05 per share in the March quarter from $3.52 per share in the prior-year period. Unadjusted profit was $699.8 million or $2.69 per share, compared to $762.1 million or $2.96 per share last year.
Prior Performance
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Most Popular
Delta Air Lines (DAL) Q2 2025 Earnings: Key financials and quarterly highlights
Delta Air Lines (NYSE: DAL) reported its second quarter 2025 earnings results today. Operating revenue remained flat versus the year-ago quarter at $16.64 billion. GAAP net income increased 63% year-over-year
PepsiCo likely to report weak Q2 results as North America demand slumps
After entering fiscal 2025 on a low note, PepsiCo, Inc. (NASDAQ: PEP) is gearing up to publish its second-quarter results. The company is facing sales pressure amid geopolitical tensions and
Bank earnings preview: These banking leaders will report Q2 2025 results next week, what to expect
The earnings season is set to kick off next week with quarterly reports from a number of leading banks. JPMorgan Chase & Co. (NYSE: JPM), Citigroup (NYSE: C) and Wells
